Literature DB >> 15801073

Pregnancy in Wegener's granulomatosis: successful treatment with intravenous immunoglobulin.

Francesca Bellisai1, Gabriella Morozzi, Roberto Marcolongo, Mauro Galeazzi.   

Abstract

We present the case of a women diagnosed with Wegener's disease at the age of 26 years, refractory to corticosteroid and cyclophosphamide therapy. Treatment with intravenous immunoglobulin (IVIg) was started, leading to partial clinical remission of disease. During IVIg treatment she became pregnant. IVIg therapy was continued, the disease went into remission, and after 40 weeks the patient delivered a healthy boy. After 6 months from the delivery, the patient became pregnant again. Now she is at the 22nd week of pregnancy and she is doing very well. This case supports the beneficial effect of IVIg in Wegener's granulomatosis and illustrates its safety and efficacy during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15801073     DOI: 10.1007/s10067-004-0932-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  15 in total

1.  Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin.

Authors:  Y Levy; Y Sherer; J George; P Langevitz; A Ahmed; Y Bar-Dayan; F Fabbrizzi; J Terryberry; J Peter; Y Shoenfeld
Journal:  Int Arch Allergy Immunol       Date:  1999-07       Impact factor: 2.749

Review 2.  Novel therapies in vasculitis.

Authors:  C Thomas-Golbanov; S Sridharan
Journal:  Expert Opin Investig Drugs       Date:  2001-07       Impact factor: 6.206

Review 3.  Prevention of fetal death in the antiphospholipid antibody syndrome.

Authors:  S Cowchock
Journal:  Lupus       Date:  1996-10       Impact factor: 2.911

4.  Relapse of Wegener's granulomatosis in the first trimester of pregnancy: a case report.

Authors:  A Kumar; A Mohan; R Gupta; V K Singal; O P Garg
Journal:  Br J Rheumatol       Date:  1998-03

5.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

Authors:  D R Jayne; H Chapel; D Adu; S Misbah; D O'Donoghue; D Scott; C M Lockwood
Journal:  QJM       Date:  2000-07

6.  Churg-Strauss syndrome and pregnancy: successful treatment with intravenous immunoglobulin.

Authors:  Samara Amaris Rutberg; David E Ward; Bernard J Roth
Journal:  J Clin Rheumatol       Date:  2002-06       Impact factor: 3.517

Review 7.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

Review 8.  [Treatment of ANCA-positive systemic vasculitis with intravenous immunoglobins].

Authors:  L Mouthon
Journal:  Rev Med Interne       Date:  1999       Impact factor: 0.728

9.  IL-1 beta production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasmic autoantibodies: relevance to systemic vasculitis.

Authors:  C J Brooks; W J King; D J Radford; D Adu; M McGrath; C O Savage
Journal:  Clin Exp Immunol       Date:  1996-11       Impact factor: 4.330

10.  Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis.

Authors:  F Rossi; D R Jayne; C M Lockwood; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

View more
  3 in total

1.  Pregnancy complicating Wegener's granulomatosis.

Authors:  May Ching Soh; Hamish H Hart; Eileen Bass; Lucille Wilkinson
Journal:  Obstet Med       Date:  2009-05-22

2.  Wegener's granulomatosis in pregnancy: a case report and review of the medical literature.

Authors:  Vinodh Nanjanna Devakumar; Madhura Castelino; Shien-Ching Chow; Lee-Suan Teh
Journal:  BMJ Case Rep       Date:  2010-01-13

Review 3.  Advances in the use of biologic agents for the treatment of systemic vasculitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.